 This test is used to aid physicians in identifying patients with metastatic colorectal cancer for treatment with Erbitux.The presence of KRAS mutations in colorectal cancer tissue indicates that the patient may not benefit from treatment with Erbitux.If the test result indicates that the KRAS mutations are absent in the colorectal cancer cells, then the patient may be considered for treatment with Erbitux.